“…Parents have been described to feel dependent on clinicians and to experience considerable unease in making decisions about trial participation [34,41,56]. Parents' communications with physicians focus more extensively on the child's illness, treatment, risks or benefits than on the RCT with its risks or procedures such as randomization [12,41,53].…”
Section: Relations and Communicationmentioning
confidence: 99%
“…Other reasons for participation which were less frequent were: "To help other people with problems" [51,56,60], "My doctor told me to be in the study" [51,60], or "My parents told me to be in the study" [60].…”
Section: Children's Perspectivesmentioning
confidence: 99%
“…Also relevant were organisational reasons such as the existence of appointments which were made for the initial medical therapy so that participation won't take much effort or the location of the clinic [42,51,56,61,62].…”
Section: Parent's Perspectivesmentioning
confidence: 99%
“…Adolescents' reasons for declining participation included increased clinic visits, increased number treatment interventions [73], increased frequency of diagnostic procedures, transportation issues and the opposition to randomization [56,73].…”
Background: Studies have shown that many drugs used in children may not have been authorised for use in this age group. This poses significant risks on children. A new EU regulation came into effect in 2007 to ensure that medicinal products that are researched, developed and authorised will also meet the therapeutic needs of children. This will mean an increased demand for children to participate in clinical trials. Objectives: To identify the needs and motivations of children and their families who have participated, might participate or declined to participate in clinical trials. Methods: We did a literature search and reviewed empirical studies which examined eligible outcomes. The findings of these studies were analyzed in a broad qualitative and descriptive bottom-up process. Results: We found that the understanding of advanced concepts of research such as randomisation is often insufficient. The needs of families affected by a serious disease are not addressed explicitly. Personal benefit and altruistic motives were two important reasons for participation. Conclusions: The comprehension of information given in the consent process should be secured by improving the information material. The communication process should be more mutual. Children and their families should be empowered to address their needs in the process of considering participation in a clinical trial.
“…Parents have been described to feel dependent on clinicians and to experience considerable unease in making decisions about trial participation [34,41,56]. Parents' communications with physicians focus more extensively on the child's illness, treatment, risks or benefits than on the RCT with its risks or procedures such as randomization [12,41,53].…”
Section: Relations and Communicationmentioning
confidence: 99%
“…Other reasons for participation which were less frequent were: "To help other people with problems" [51,56,60], "My doctor told me to be in the study" [51,60], or "My parents told me to be in the study" [60].…”
Section: Children's Perspectivesmentioning
confidence: 99%
“…Also relevant were organisational reasons such as the existence of appointments which were made for the initial medical therapy so that participation won't take much effort or the location of the clinic [42,51,56,61,62].…”
Section: Parent's Perspectivesmentioning
confidence: 99%
“…Adolescents' reasons for declining participation included increased clinic visits, increased number treatment interventions [73], increased frequency of diagnostic procedures, transportation issues and the opposition to randomization [56,73].…”
Background: Studies have shown that many drugs used in children may not have been authorised for use in this age group. This poses significant risks on children. A new EU regulation came into effect in 2007 to ensure that medicinal products that are researched, developed and authorised will also meet the therapeutic needs of children. This will mean an increased demand for children to participate in clinical trials. Objectives: To identify the needs and motivations of children and their families who have participated, might participate or declined to participate in clinical trials. Methods: We did a literature search and reviewed empirical studies which examined eligible outcomes. The findings of these studies were analyzed in a broad qualitative and descriptive bottom-up process. Results: We found that the understanding of advanced concepts of research such as randomisation is often insufficient. The needs of families affected by a serious disease are not addressed explicitly. Personal benefit and altruistic motives were two important reasons for participation. Conclusions: The comprehension of information given in the consent process should be secured by improving the information material. The communication process should be more mutual. Children and their families should be empowered to address their needs in the process of considering participation in a clinical trial.
“…26 Therefore, the relatively low enrollment rate and the need to include the preference cohort were not unexpected but resulted in a primary analysis that was an as-treated assessment rather than an intention-to-treat assessment. Potential bias due to nonrandom treatment assignment in this analysis is expected to be minimized, but is not eliminated, by the use of propensityscore adjustment.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.